GT Biopharma Dividends
| GTBP Stock | USD 2.79 0.01 0.36% |
As of 12/03/2024, Dividend Paid And Capex Coverage Ratio is likely to drop to -358.12. GT Biopharma's past performance could be the main factor of why investors trade GT Biopharma stock today. Investors should clearly understand every aspect of the GT Biopharma dividend schedule, including its future sustainability, and how it might impact an overall investment strategy. This tool is helpful to digest GT Biopharma's dividend schedule and payout information. GT Biopharma dividends can also provide a clue to the current valuation of GT Biopharma.
| Last Reported | Projected for Next Year | ||
| Dividend Paid And Capex Coverage Ratio | (341.07) | (358.12) |
GTBP |
Investing in stocks that pay dividends is one of many strategies that are good for long-term investments. Ex-dividend dates are significant because investors in GT Biopharma must own a stock before its ex-dividend date to receive its next dividend.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GT Biopharma. If investors know GTBP will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GT Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.39) | Return On Assets (0.61) | Return On Equity (1.31) |
The market value of GT Biopharma is measured differently than its book value, which is the value of GTBP that is recorded on the company's balance sheet. Investors also form their own opinion of GT Biopharma's value that differs from its market value or its book value, called intrinsic value, which is GT Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GT Biopharma's market value can be influenced by many factors that don't directly affect GT Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GT Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if GT Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GT Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.